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Hyperproliferation	of	bile	duct	epithelial	cells	due	to	cell-cycle	dysregulation	is	a	key	feature	of	cystogenesis	
in	polycystic	liver	diseases	(PCLDs).	Recent	evidence	suggests	a	regulatory	role	for	microRNAs	(miRNAs)	in	
a	variety	of	biological	processes,	including	cell	proliferation.	We	therefore	hypothesized	that	miRNAs	may	
be	involved	in	the	regulation	of	selected	components	of	the	cell	cycle	and	might	contribute	to	hepatic	cysto-
genesis.	We	found	that	the	cholangiocyte	cell	line	PCK-CCL,	which	is	derived	from	the	PCK	rat,	a	model	of	
autosomal	recessive	polycystic	kidney	disease	(ARPKD),	displayed	global	changes	in	miRNA	expression	com-
pared	with	normal	rat	cholangiocytes	(NRCs).	More	specific	analysis	revealed	decreased	levels	of	1	miRNA,	
miR15a,	both	in	PCK-CCL	cells	and	in	liver	tissue	from	PCK	rats	and	patients	with	a	PCLD.	The	decrease	in	
miR15a	expression	was	associated	with	upregulation	of	its	target,	the	cell-cycle	regulator	cell	division	cycle	
25A	(Cdc25A).	Overexpression	of	miR15a	in	PCK-CCL	cells	decreased	Cdc25A	levels,	inhibited	cell	prolif-
eration,	and	reduced	cyst	growth.	In	contrast,	suppression	of	miR15a	in	NRCs	accelerated	cell	proliferation,	
increased	Cdc25A	expression,	and	promoted	cyst	growth.	Taken	together,	these	results	suggest	that	suppres-
sion	of	miR15a	contributes	to	hepatic	cystogenesis	through	dysregulation	of	Cdc25A.
Introduction
Polycystic liver diseases (PCLDs) are genetically heterogeneous 
and occur alone or in combination with polycystic kidney dis-
ease (PKD) (1, 2). Autosomal dominant PCLD (ADPLD) dis-
plays no renal involvement and is caused by a mutation of the 
gene protein kinase substrate 80K-H (PRKCSH), which encodes 
the protein hepatocystin (3). PKD is a genetic nephrohepatic 
cystic disease and can be inherited in an autosomal dominant 
(ADPKD) or autosomal recessive (ARPKD) fashion. ADPKD 
is more common and is linked to mutations in either PKD1 or 
PKD2, genes that encode the proteins polycystin 1 and polycys-
tin 2, respectively (4). ARPKD is caused by mutations of the gene 
polycystic kidney and hepatic disease 1 (PKHD1), which encodes 
the protein fibrocystin/polyductin (5, 6). ARPKD has a high 
mortality rate, with approximately 30% of affected neonates 
dying within hours after birth because of respiratory difficulties 
due to enlarged kidneys. In surviving patients, hepatic lesions 
become progressively more severe with age; liver disease is the 
major cause of morbidity and mortality and is characterized by 
biliary dysgenesis associated with congenital hepatic fibrosis 
(CHF), bile duct dilatation, and cyst formation (2, 7).
The mechanisms involved in the pathogenesis of liver cysts in 
the PCLDs are unclear. However, it is likely that hyperprolifera-
tion of bile duct epithelial cells (i.e., cholangiocytes) plays a major 
role in hepatic cyst growth and expansion. Indeed, in the PCK rat, 
a well-characterized animal model of ARPKD (6, 8), bile ducts are 
markedly distorted, displaying multiple saccular dilatations and 
many hepatic cysts of different sizes (9). Moreover, overgrowth 
of liver cysts is associated with increased proliferative activity of 
cystic cholangiocytes in PCK rats compared with age-matched 
normal rats (10, 11). Finally, in a spontaneously immortalized 
cholangiocyte cell line derived from the PCK rat (PCK-CCL) that 
retains the in vivo phenotype of cystic cholangiocytes, the rate 
of cell proliferation is significantly higher and the doubling time 
twice as fast as in a cell line derived from normal rats (normal rat 
cholangiocytes [NRCs]) (12).
It is known that accelerated cell proliferation is related to altera-
tions in the cell cycle. Cell proliferation is a complex process that 
is regulated by different cellular components, including protein 
kinases and phosphatases. Cell division cycle 25 (Cdc25), a fam-
ily of dual-specificity phosphatases, plays an essential role in cell-
cycle progression by activating cyclin-dependent kinases (Cdks) 
(13). Three Cdc25 isoforms (Cdc25A, Cdc25B, and Cdc25C) have 
been identified (14, 15). Although Cdc25B and Cdc25C contrib-
ute to cell-cycle regulation, Cdc25A is principally responsible for 
G1-S and G2-M transitions (16). Importantly, the overexpression 
of Cdc25A and Cdc25B in a number of cancers is frequently cor-
related with tumor grade and aggressiveness as well as with poor 
prognosis (17). Thus, Cdc25 phosphatases have become a new 
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pharmacological target in cancer therapy (18). However, there are 
no data on the Cdc25 activity associated with benign, hyperprolif-
erative diseases such as the PCLDs.
Accumulating evidence suggests that expression of genes 
involved in many cellular processes is regulated by small noncod-
ing RNAs (i.e., microRNAs [miRNAs]) that posttranscriptionally 
inhibit target mRNA transcripts via sequence-specific base pairing 
(19). Biochemical and genetic studies suggest that miRNAs play 
important roles in a variety of cellular processes, including differ-
entiation, apoptosis, and cell proliferation (20). In particular, the 
miR17 cluster and miR21 are known to promote cell prolifera-
tion (21), while miR15a, miR16, and the family of let-7 miRNAs 
suppress cell proliferation (22, 23). Moreover, many cancers are 
characterized by aberrant expression of miRNAs, with a majority 
of the miRNAs being substantially reduced (24, 25). However, no 
data describing the profiling and role of miRNAs in the patho-
genesis of PCLDs exist.
In the present study, we employed in vivo (the PCK and normal rats) 
and in vitro (cholangiocyte cell lines derived from PCK [PCK-CCL] 
and from normal [NRCs] rats) models to examine the following: 
(a) miRNA profiles; (b) expression of Cdc25A message and protein; 
(c) role of miR15a in posttranscriptional regulation of Cdc25A; (d) 
effect of experimental modulation of miR15a levels on cell-cycle 
distribution and rate of cholangiocyte proliferation; and (e) effect 
of miR15a modulation on cyst growth and expansion. We also 
assessed expression of miR15a and Cdc25A in normal human liv-
ers and in livers of patients with ADPKD, ARPKD, and CHF.
Our data show a relationship between cholangiocyte prolifera-
tion and upregulation of Cdc25A, an important cell-cycle regu-
lator. Moreover, these data suggest that Cdc25A overexpression 
is due to posttranscriptional inhibition by miR15a and that this 
regulatory pathway is involved in hepatic cystogenesis.
Results
The rate of cell proliferation and the mitotic index are increased in PCK-CCL. 
Rates of cell proliferation in PCK-CCL and NRCs were measured 
over time. Consistent with our previous observation (12), PCK-CCL 
showed higher proliferation rates (~2-fold) at every time point 
analyzed (Figure 1A). The calculated doubling time was twice 
as fast in PCK-CCL (~28.8 hours) compared with that of NRCs 
(~58.1 hours; P < 0.05).
To evaluate mitotic rates in PCK-CCL, the number of cells with 
mitotic spindles (i.e., mitotic indices) was assessed by immuno-
fluorescent confocal microscopy. Our data demonstrated that in 
PCK-CCL, mitotic indices were approximately 5-fold greater com-
pared with in NRCs (Figure 1, B and C).
Expression of miRNAs is altered in PCK-CCL. To identify potential 
miRNAs that might regulate the expression of proteins involved 
in cell-cycle progression and thus influence the accelerated rate 
of proliferation in PCK-CCL, we performed microarray analysis 
of miRNA profiles in NRCs and PCK-CCL and found that the 
expression of miRNAs in PCK-CCL was markedly different from 
that in NRCs (Supplemental Table 1; supplemental material 
available online with this article; doi:10.1172/JCI34922DS1). In 
total, subsets of 121 and 148 miRNAs were detected in NRCs and 
PCK-CCL, respectively. Twelve miRNAs were present in NRCs but 
not in PCK-CCL, and 39 miRNAs were present only in PCK-CCL. 
Moreover, 109 miRNAs common to both cell lines were differen-
tially expressed in PCK-CCL. Interestingly, of the differentially 
expressed miRNAs, most (i.e., 97 miRNAs, or 89%) were downreg-
ulated in PCK-CCL compared with NRCs, and 12 miRNAs (11%) 
were overexpressed in cystic cholangiocytes.
Expression of miRNA15a is reduced in vitro and in vivo in cystic chol-
angiocytes. Microarray analysis revealed that the level of 1 of the 
miRNAs present in both cell lines, miR15a, was decreased 37-fold 
in PCK-CCL compared with in NRCs, being by far the most sup-
pressed miRNA (Figure 2, A and B). To validate the microarray plat-
form, we assessed the expression of miR15a in NRCs and PCK-CCL 
by Northern blot analysis. By this approach, we confirmed a 
decrease in miR15a expression in PCK-CCL, although the differ-
ence was smaller (~4-fold; Figure 2C). We also examined levels of 
miR15a in freshly isolated cholangiocytes of normal and PCK rats 
by quantitative PCR. Consistent with our in vitro data, expres-
sion of miR15a in cystic cholangiocytes of PCK rats was decreased 
approximately 8-fold compared with in normal rats (Figure 2D). 
Thus, reduced expression of miR15a in cystic cholangiocytes was 
observed by several independent techniques in vitro and in vivo.
To assess the levels of miR15a in whole-liver tissue of normal 
and PCK rats and in liver tissue of normal humans and patients 
with ADPKD, ARPKD, and CHF, we applied locked nucleic acid 
in situ hybridization (LNA-ISH). Locked nucleic acid–modified 
oligonucleotide probes have been successfully used to visualize 
Figure 1
Rates of cell proliferation and mitotic indices in NRCs and PCK-CCL. (A) In PCK-CCL, the rate of cell proliferation (determined by MTS absor-
bance at 490 nm) was significantly higher at each time point. Data are representative of 5 independent experiments. (B) Mitotic figures (asterisks) 
in NRCs and PCK-CCL were assessed by immunofluorescent confocal microscopy using an anti–α-tubulin antibody as a marker for microtubules 
(red). Nuclei were stained with DAPI (blue). Original magnification, ×60. (C) Quantitative analysis shows that in PCK-CCL, the number of mitotic 
cells (>500 cells counted in each experiment) was significantly greater compared with NRCs. *P < 0.05.
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miRNAs in whole-mount preparations of zebrafish (26) and in 
human brain tissue (27). Unlike with the mismatch control probe 
(i.e., scrambled miRNA), hybridization with the miR15a-specific 
probe revealed the presence of miR15a in normal and cystic chol-
angiocytes. However, the intensity of miR15a immunoreactivity in 
cholangiocytes lining liver cysts in patients with ADPKD, ARPKD, 
and CHF and in the PCK rat was reduced compared with that in 
normal human cholangiocytes and NRCs (Figure 3).
Cdc25A is one of the potential targets of miR15a. By an in silico 
approach, we identified that 1 of the potential targets of miR15a 
is the family of Cdc25 dual-specificity phosphatases that play an 
essential role in cell-cycle progression. Moreover, miR15a has a 
conserved complementarity to Cdc25A mRNA (Table 1). Using a 
rat genomic DNA database search, the 83-bp miR15a precursor 
sequence, including 22-bp miR15a, was detected at rat chromo-
some 15. Sequencing of the miR15a precursor region showed no 
polymorphisms in the genomic DNA from NRCs and PCK-CCL.
We also searched for any other miRNAs that could potentially 
bind to Cdc25A mRNA. Thirty-one miRNAs with partial or com-
plete complementarity to Cdc25A mRNA were found. However, 
only 8 of them were present in both cell lines (Table 2). Two of 
them, miR34a and miR107, were expressed only in PCK-CCL.
Cdc25A protein expression is increased in cystic cholangiocytes in vitro and 
in vivo, while Cdc25A mRNA levels are not different. Next, we analyzed 
the expression of Cdc25A at the message and protein levels in NRCs 
and PCK-CCL and in freshly isolated cholangiocytes from normal 
and PCK rats. By RT-PCR, we found no significant differences in 
Cdc25A mRNA levels between NRCs and PCK-CCL (Figure 4, A 
and B). This result was confirmed in freshly isolated cholangiocytes 
(Figure 4, C and D). However, the expression of Cdc25A protein 
assessed by Western blot was significantly higher in PCK-CCL (~3 
times) and PCK cholangiocytes (~2 times) compared with NRCs 
and cholangiocytes isolated from normal rats, respectively (Figure 
4, E–H). The differences in Cdc25A expression at mRNA and pro-
tein levels suggested that miRNAs might be involved in posttran-
Figure 2
Expression of miR15a in normal and cystic cholangiocytes in vitro and in vivo. (A and B) As shown by microarray analysis, miR15a was down-
regulated 37-fold in PCK-CCL compared with NRCs. Scale bars: 1000 μm (microarray images); 100 μm (insets). (C) Using Northern blot, we 
detected smaller (~4-fold) changes in expression of miR15a in PCK-CCL. (D) Consistent with in vitro data, miR15a levels were decreased in 
cholangiocytes freshly isolated from PCK rats compared with those in normal rats as assessed by quantitative PCR. *P < 0.05.
Figure 3
Expression of miR15a in human and rat liver tissue by locked nucleic 
acid in situ hybridization. Intensity of miR15a immunoreactivity in chol-
angiocytes lining liver cysts in patients with ADPKD, ARPKD, and CHF 
and in the PCK rat was reduced compared with that in normal human 
cholangiocytes and NRCs. No staining was observed in liver tissue 
hybridized with scrambled (scr) miRNA. Original magnification, ×100 
(normal human and normal rat); ×63 (ADPKD, ARPKD, CHF, and PCK 
rat). Asterisks indicate bile duct or cyst lumen. Data are representative 
of 3 independent experiments.
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scriptional regulation of the Cdc25A protein. Expression of Cdc25A 
was also assessed by immunofluorescent confocal microscopy in 
liver tissue of the PCK and normal rats and in liver tissue of normal 
humans and patients with ARPKD, ADPKD, and CHF. Representa-
tive images in Figure 5 show that immunoreactivity of Cdc25A was 
higher in cholangiocytes lining liver cysts in humans and PCK rats 
compared with normal human cholangiocytes and NRCs.
Modulation of miR15a alters the expression of Cdc25A protein in tran-
siently transfected PCK-CCL. To support the notion that posttran-
scriptional regulation of Cdc25A by miR15a might contribute to 
increased Cdc25A protein expression, PCK-CCL was transfected 
with FITC-labeled miR15a, and Cdc25A expression was assessed 
by confocal immunofluorescent microscopy. As shown in Figure 6, 
A and B, we observed significantly reduced fluorescent immunore-
activity of Cdc25A in FITC-labeled miR15a-transfected cells com-
pared with nontransfected PCK-CCL.
To further support the notion that miR15a posttranscription-
ally regulates the level of Cdc25A protein, we transfected PCK-CCL 
with a miR15a precursor (pre-miR15a) and assessed the levels of 
miR15a by quantitative PCR. PCK-CCL transfected with scram-
bled miRNA was used as a control. Data presented in Figure 6C 
demonstrate that levels of miR15a were increased in pre-miR15a 
PCK-CCL compared with cystic cholangiocytes transfected with 
scrambled miRNA. Consistent with our prediction, overexpression 
of miR15a in PCK-CCL was associated with an approximately 50% 
reduction in the level of Cdc25A protein (Figure 6, D and E).
Modulation of miR15a alters the cell cycle in transiently transfected PCK-CCL. 
Cdc25A is an important cell-cycle regulator and plays a major role 
in G1-S transition. Based on our data that experimental modula-
tion of miR15a altered Cdc25A protein expression, we predicted 
that it would also affect the cell cycle in PCK-CCL. To this end, we 
assessed the cell-cycle phase distribution in pre-miR15a PCK-CCL 
by FACS analysis and found that the portion of G1 phase cells was 
increased by 23% while the portion of cells in S phase was reduced 
by 37.2% compared with that in PCK-CCL treated with scrambled 
miRNA only (Figure 6F). These data suggest that suppression of 
Cdc25A by miR15a induces inhibition of G1-S cell-cycle transition, 
resulting in accumulation of cholangiocytes in the G1 phase.
miR15a suppresses Cdc25A by binding to the 3′-UTR region. To directly 
address whether miR15a binds to the Cdc25A mRNA, leading to 
its translational suppression, we generated a pMIR-REPORT lucif-
erase construct containing Cdc25A mRNA 3′-UTR region with 
the putative miR15a-binding site (Cdc25A WT). In addition, we 
generated another pMIR-REPORT luciferase construct contain-
ing Cdc25A mRNA 3′-UTR region with a mutation at the puta-
tive miR15a-binding site (Cdc25A mutant; Figure 7A). As shown 
in Figure 7B, in PCK-CCL cotransfected with miR15a precursor 
and Cdc25A WT construct, luciferase reporter translation was 
decreased by 75.1% compared with that in PCK-CCL transfected 
with Cdc25A WT construct only. However, in PCK-CCL cotrans-
fected with miR15a precursor and Cdc25A mutant construct, 
expression of luciferase reporter was not inhibited. We also did not 
observe any significant changes in expression of luciferase reporter 
in PCK-CCL cotransfected with scrambled miRNA and Cdc25A 
WT or Cdc25A mutant. These data suggest that miR15a regulates 
Cdc25A protein expression through direct binding to the 3′-UTR 
region of Cdc25A mRNA.
Cell proliferation is decreased in stably transfected PCK-CCL overex-
pressing miR15a. To evaluate the effect of miR15a on cell prolifera-
tion and cyst growth, we established a stable cell line (PCK-CCL– 
pSR-miR15a) that overexpressed miR15a. Quantitative PCR dem-
onstrated that expression of miR15a was increased in PCK-CCL– 
pSR-miR15a compared with nontransfected PCK-CCL or PCK-
CCL transfected with empty vector (EV) (PCK-CCL–pSR-EV; 
Figure 8A). Importantly, in PCK-CCL–pSR-miR15a, the rate of 
cholangiocyte proliferation was inhibited compared with that 
in PCK-CCL–pSR-EV (Figure 8B) and the doubling time was 
increased from 25 hours to 31 hours (P < 0.05).
The rate of cyst growth is decreased in PCK-CCL overexpressing miR15a. 
We have previously shown that PCK-CCL seeded in 3D culture 
organizes into cystic structures that continue to expand progres-
sively over time (12). Thus, we evaluated the effect of miR15a 
overexpression on growth of cysts formed by both PCK-CCL–pSR-
miR15a and PCK-CCL–pSR-EV. Cystic surface area was assessed 
at days 3, 6, 9 and 12 for each cell line. We found that 75% of cysts 
formed by PCK-CCL–pSR-EV progressively grew over time (Fig-
ure 8C). In contrast, all cysts formed by PCK-CCL–pSR-miR15a 
did not expand, as assessed by light microscopy and quantitative 
analysis of cystic surface areas (Figure 8D). Importantly, inhibition 
of cyst growth was more dramatic than the effect of miR15a on the 
rate of cholangiocyte proliferation, suggesting that miR15a may 
affect expression of other genes related to cystogenesis.
Cell proliferation, Cdc25A protein expression, and cyst growth are 
affected by downregulation of miR15a in NRCs. To further prove that 
miR15a is involved in regulation of Cdc25A protein expression 
and subsequently affects cell proliferation and cyst growth, we 
reduced miR15a levels in normal cholangiocytes with a miR15A 
antisense (anti-miR15a). Figure 9A demonstrates that both anti-
miR15a and scrambled miRNA labeled with Cy3 dye were pres-
ent in treated cholangiocytes compared with nontreated cells. 
Table 1
miR15a:Cdc25A-mRNA complementarity in human and rat
mRNA	 Sequence
miR15a        GUGUUUGGUAAUACACGACGAU 5′
Rno Cdc25A 5′                   CACUGAAGUGCUGCUG
Mmu Cdc25A 5′                   CGCCCAAGUGCUGCUG
Hsa Cdc25A 5   GAAGUUACACAGAAAUGCUGCUG
Seed match is denoted by bold letters.
Table 2
Expression profile of miRNAs that can potentially bind 
Cdc25A mRNA
miRNAs	 RatioA	 	 Fold	change
	 NRCs	 PCK-CCL
miR15a 6.4 0.2 –37.3
miR34a – 0.2
miR103 0.5 0.4 –1.1
miR107 – 1.0
miR195 0.4 0.1 –3.3
miR204 59.0 6.5 –9.0
miR326 47.3 5.9 –8.0
miR331 1.2 0.4 –3.2
ARatio represents gene signal intensity normalized to tRNAmet signal 
intensity.
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Quantitative PCR revealed that miR15a expression was decreased 
in NRCs exposed to anti-miR15a compared with cholangiocytes 
exposed to vehicle or scrambled miRNA (Figure 9B). Downregu-
lation of miR15a in normal cholangiocytes affected Cdc25A pro-
tein expression, cholangiocyte proliferation, and cyst growth. As 
shown in Figure 9, C and D, in the presence of anti-miR15a, the 
level of its target, Cdc25A, was significantly increased compared 
with levels in scrambled miRNA. Upregulation of Cdc25A was 
accompanied by a mildly increased rate of cholangiocyte prolif-
eration (Figure 9E). We also examined the effect of miR15a inhibi-
tion on cyst growth by assessing the changes in the area of cystic 
structures formed by normal cholangiocytes in 3D culture during 
5 days (days 0–4). In the presence of both scrambled miRNA and 
anti-miR15a, normal cholangiocytes progressively expanded over 
time. However, the rate of cyst growth was significantly accelerat-
ed in cholangiocytes treated with anti-miR15a (Figure 9, F and G). 
These data further support the notion that the miR15a/Cdc25A 
complex plays an important role in regulation of cholangiocyte 
proliferation and cyst growth.
Discussion
In the present study, we found the following: (a) cholangiocytes 
derived from the PCK rat display global changes in miRNA 
expression compared with NRCs; (b) miR15a has complementa-
rity to Cdc25A mRNA and is downregulated in vitro in PCK-CCL 
and in vivo in bile ducts of the PCK rat; (c) increased cholangio-
cyte proliferation is accompanied by overexpression of Cdc25A 
in PCK-CCL; (d) reduced miR15a expression is associated with 
increased levels of Cdc25A in patients with ADPKD, ARPKD, 
and CHF; (e) experimental modulation of miR15a changes the 
levels of Cdc25A protein; (f) overexpression of miR15a in cystic 
cholangiocytes inhibits G1-S cell-cycle transition, cholangio-
cyte proliferation, and cyst growth; and (g) downregulation of 
miR15a in normal cholangiocytes increases cell proliferation 
and Cdc25A expression and accelerates cyst growth. Overall, 
our data suggest that the miR15a/Cdc25A complex plays an 
important role in dysregulation of the cell cycle and subsequent 
growth of liver cysts in the PCLDs.
Hyperproliferation of cholangiocytes is considered to be one 
of the major causative mechanisms involved in hepatic cystogen-
esis in the PCLDs (1). It is also known that increased rates of cell 
proliferation are related to cell-cycle dysregulation. In the work 
described here, we demonstrate for what we believe is the first time 
that Cdc25A, a cell-cycle regulator, is overexpressed in cholangio-
Figure 4
Expression levels of Cdc25A mes-
sage and protein in vitro (NRCs and 
PCK-CCL) and in vivo (freshly isolat-
ed cholangiocytes from normal and 
PCK rats). Using RT-PCR, we found 
no significant differences in Cdc25A 
mRNA levels in the PCK–CCL 
(A and B) and PCK rats (C and D) 
compared with NRCs and normal 
rats, respectively. In contrast, levels 
of Cdc25A protein expression were 
significantly higher in the PCK–CCL 
(E and F) and PCK rats (G and H) 
compared with NRCs and normal 
rats, respectively. Data are represen-
tative of 3 independent experiments. 
*P < 0.05.
Figure 5
Expression of Cdc25A in liver tissue by immunofluorescent confocal 
microscopy. Levels of Cdc25A were increased in cholangiocytes lining 
rat and human liver cysts compared with normal cholangiocytes. Origi-
nal magnification, ×100 (normal human and normal rat); ×63 (ADPKD, 
ARPKD, CHF, PCK rat). Asterisks indicate bile duct or cyst lumen. 
Data are representative of 3 independent experiments.
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cytes lining liver cysts in the PCK rat and in patients with cystic 
liver diseases. Moreover, we identified a potential mechanism of 
Cdc25A upregulation, namely, posttranscriptional regulation 
of its expression by miR15a. Indeed, experimental inhibition of 
miR15a in normal cholangiocytes increases Cdc25A protein levels, 
subsequently resulting in accelerated cell proliferation and more 
rapid cyst growth. Further, as a result of Cdc25A suppression by 
miR15a in PCK-CCL due to its experimental overexpression, we 
observed inhibition in G1-S transition, cholangiocyte prolifera-
tion, and rate of cyst formation. The data raise the possibility of 
a new therapeutic approach to the nephrohepatic cystic diseases 
— cell-cycle modulation via miRNAs.
Multiple lines of evidence have demonstrated an important 
role of miRNAs in the regulation of expression of genes involved 
in different cellular processes, in particular, in cell proliferation 
(22, 23, 28). To this end, we examined miRNA profiles in normal 
and PCK cholangiocytes by microarray analysis and found that 
the levels of miRNAs in PCK-CCL are remarkably different from 
that in NRCs. Moreover, 1 of the miRNAs, miR15a (known to 
be associated with regulation of cell proliferation; ref. 22) was 
decreased 37-fold in PCK-CCL. Microarray analysis in some 
cases shows larger changes in gene expression compared with 
other techniques used to validate gene expression, since fluo-
rescence intensities of microarray probes might be affected by 
other factors, such as variations in probe concentrations and the 
efficiency of printing pins (29, 30). Indeed, by Northern blot, we 
detected smaller changes in expression of miR15a. Importantly, 
these changes were comparable with changes in levels of miR15a 
detected in freshly isolated PCK cholangiocytes by quantitative 
PCR. Downregulation of miR15a in cystic cholangiocytes in vivo 
was further confirmed by in situ hybridization.
Using an in silico approach, we found that miR15a has comple-
mentarity to Cdc25A. To directly address whether miR15a binds 
to Cdc25A mRNA, resulting in translational suppression, we used 
a pMIR-REPORT luciferase construct containing the Cdc25A 
mRNA 3′-UTR region with the putative miR15a-binding site. Our 
data showed that miR15a directly binds to the 3′-UTR region of 
Cdc25A mRNA, resulting in specific translational suppression. 
We recognize that other miRNAs may also be involved in regu-
lation of Cdc25A expression. Indeed, in NRCs and PCK-CCL, 5 
other miRNAs that could potentially bind to Cdc25A (miR103, 
miR195, miR204, miR326, and miR331) were found and were 
also downregulated in PCK-CCL. The data raise the possibility of 
posttranscriptional regulation of Cdc25A by multiple miRNAs. 
Interestingly, let-7 miRNA was recently implicated in regulation of 
Cdc25A expression in human lung cancer cells (28).
To further evaluate a potential role of miR15a/Cdc25A complex 
in liver cystogenesis, we employed a 3D culture system. Consis-
tent with our previous data (12), cystic and normal cholangiocytes 
grown between 2 layers of collagen/Matrigel formed spherical cys-
tic structures that progressively expanded over time. Inhibition 
of miR15a in normal cholangiocytes resulted in accelerated cyst 
growth. In contrast, and consistent with our hypothesis, experi-
mental restoration of miR15a levels in PCK-CCL suppressed cyst 
growth. These results suggest that the miR15a/Cdc25A complex 
is involved in hepatic cystogenesis.
Figure 6
Effect of miR15a modulation on Cdc25A protein expression in transiently transfected PCK-CCL. (A) Fluorescence confocal images and quantita-
tive analysis based on fluorescence intensity (B) demonstrate that in PCK-CCL transfected with FITC- labeled miR15a (green spots), expres-
sion of Cdc25A (red) was significantly decreased (n = 100 cells for each cell line) compared with that in PCK-CCL treated with vehicle (V) only. 
Original magnification, ×100. (C) Using quantitative PCR, we found that levels of miR15a were increased in PCK-CCL transfected with miR15a 
precursor (pre-miR15a) compared with those in cholangiocytes transfected with scrambled miRNA. Data are representative of 3 independent 
experiments. (D) Representative Western blot and quantitative analysis (E) based on densitometry measurements of 3 independent experiments 
demonstrate that protein levels of Cdc25A in the pre-miR15a PCK-CCL were decreased by 50%. (F) In the pre-miR15a PCK-CCL, the portion of 
G1 phase cells was increased while the portion of S phase cells was reduced compared with those in PCK-CCL treated with scrambled miRNA. 
Data are representative of 5 independent experiments. *P < 0.05.
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Our data show that miRNAs are differentially expressed in cystic 
cholangiocytes, i.e., the majority of miRNAs (89%) are downregu-
lated in PCK-CCL, while 11% of miRNAs are upregulated. Differ-
ential expression of miRNAs has also been observed in cancers, 
with downregulation being more common than upregulation 
(25, 31, 32). While the precise mechanisms by which miRNAs 
are altered in cholangiocytes lining liver cysts remain unclear, 
substantial evidence exists (1, 2, 7, 33, 34) that many cellular pro-
cesses are disturbed in cystic cells as a result of genetic mutations 
associated with PCLDs. Thus, it seems reasonable to assume, and 
our data suggest, that miRNA biogenesis may be one of these cel-
lular processes. miRNAs are transcribed as long primary precur-
sor transcripts (pri-miRNAs) that are cleaved into pre-miRNAs 
(~70-nt precursor hairpins) by the RNase III–like enzyme Drosha 
(35). The pre-miRNAs are exported to the cytoplasm by exportin 
5 (36) and cleaved to short, partially double-stranded RNA, about 
22 nucleotides long, in which 1 strand is the mature miRNA. The 
mature miRNA then binds to specific messenger RNA targets and 
mediates either translation repression or direct mRNA cleavage. In 
principle, since miRNA biogenesis is a highly regulated multistep 
process, levels of miRNA expression can be regulated at several dif-
ferent levels: (a) pri-miRNA transcription; (b) Drosha-dependent 
pri-miRNA processing; (c) nuclear export; (d) Dicer-dependent 
processing into mature miRNAs; and (e) miRNA turnover. Thus, 
defects at any level of miRNA processing could be responsible for 
the final levels of miRNA expression. Consistent with this notion, 
the lack of correlation between pre-miRNA and mature miRNA 
expression levels was recently observed in human cancer (37). Our 
results show that in PCK-CCL transfected with pre-miR15a, levels 
of Cdc25A protein expression (Figure 6), G1-S cell-cycle transi-
tion (Figure 6), and cholangiocyte proliferation (Figure 8B) are all 
decreased. These data suggest that at least at this level (i.e., process-
ing of premature miRNA to mature miRNA), miR15a biogenesis is 
not affected. However, dysregulation of any other steps of miRNA 
processing could account for observed changes.
In conclusion, our data suggest that abnormalities in the miR15a/
Cdc25A complex play an essential role in the regulation of cell-cycle 
progression via posttranscriptional modulations of Cdc25A pro-
tein expression and thereby contribute to cholangiocyte hyperp-
roliferation and subsequent hepatic cyst growth and expansion. 
Thus, pharmacologic suppression of cell-cycle progression appears 
to be a potential therapeutic approach to limiting exaggerated cell 
proliferation in benign hyperproliferative conditions. Given the key 
role played by Cdks in the control of the cell-cycle machinery, both 
Cdks and their regulators, Cdc phosphatases, may represent major 
pharmacological or biological targets (18). Indeed, effective arrest 
of renal cystic disease by treatment with a Cdk inhibitor, rosco-
vitine, has recently been reported in jck and cpk mouse models of 
PKD (38). However, the effect of roscovitine of hepatic cyst growth 
was not evaluated in that study. Moreover, to our knowledge, no 
studies describing the effect of suppression of any of the cell-cycle 
regulators on progression of liver cysts have been performed. While 
no miRNA therapies of any pathological conditions have been 
reported, our data suggest that the modulation of miRNA expres-
sion should be considered a potential therapeutic approach in the 
benign hyperproliferative diseases. Furthermore, since accumulat-
ing evidence suggests that miRNA profiling is more specific than 
mRNA profiling and is very informative, miRNA expression profil-
ing may also be considered as a new diagnostic tool in the PCLDs. 
Indeed, individual miRNAs and miRNA signatures have already 
been shown to have prognostic value in some cancers (24, 31).
Methods
Animals and cell culture. WT Sprague-Dawley and PCK rats were maintained 
on a standard laboratory diet after protocols were approved by the Mayo 
Institutional Animal Care and Use Committee. Animals were anesthetized 
with pentobarbital (50 mg/kg BW, intraperitoneally). Normal and cystic 
cholangiocytes were isolated as previously described (39). Cholangiocyte 
cell lines derived from the normal rat (NRCs) and the PCK rat (PCK-CCL) 
were grown as previously described (12). Cultured cells retained the char-
acteristics of cholangiocytes, since they are positive for the epithelial cell 
marker CK-19 and respond to cAMP activation by accelerating rates of 
proliferation (data not shown).
Cell proliferation. PCK-CCL and NRCs (2,500 cells/well) were incubated 
(37°C, 5% CO2, and 100% humidity) for 48–72 hours before assays. Rates of 
cell proliferation were determined using CellTiter 96 AQueous One Solution 
Cell Proliferation Assay (Promega), as previously described (12). To study 
the effect of miR15a suppression in normal cholangiocytes, NRCs were 
treated with 50 nM of either anti-miR15a (Ambion; Applied Biosystems) 
or scrambled miRNA at day 0 and day 2 and then harvested at day 4. Rates 
of cell proliferation were determined using Click-iT EdU Alexa Fluor 488 
Cell Proliferation Assay Kit for flow cytometry (Invitrogen).
Figure 7
Targeting of miR15a to the 3′-UTR region of Cdc25A mRNA. (A) 2 
reporter constructs (Cdc25A WT and Cdc25A mutant) with the poten-
tial binding site for miR15a in the 3′-UTR region of Cdc25A were gen-
erated. (B) In PCK-CCL cotransfected with the Cdc25A WT construct 
and miR15a precursor (pre-miR15a), luciferase reporter translation 
was significantly decreased compared with that in PCK-CCL trans-
fected with the Cdc25A WT construct only. A mutation in the miR15a–
binding sequence in the Cdc25A mRNA 3′-UTR eliminated this effect. 
Moreover, in the presence of scrambled miRNA (scr miR), no changes 
in luciferase reporter were observed. Data are representative of 7 inde-
pendent experiments. *P < 0.05.
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RNA isolation and RT-PCR. RNA was isolated from freshly isolated or cul-
tured cholangiocytes with TRIzol Reagent (Invitrogen) and cDNA synthe-
sized using the SuperScript III kit (Invitrogen). Primers corresponding to 5′ 
and 3′ regions of the Cdc25A (forward, AAGGCAAACCTGTTAAGTGTG; 
reverse, GGGTACACTTCAACATTCCAG), were designed and synthesized 
by Mayo Advanced Genomics Technology Center. PCR was performed for 
35 cycles, each consisting of denaturation at 94°C for 1 minute, annealing 
at 55°C for 1 minute, and extension at 72°C for 1 minute. 18S rRNA was 
amplified to confirm an equal amount of total mRNA in samples and was 
used as normalized control. The intensity of the signals was quantified 
using a PhosphorImager (Molecular Dynamics Inc.). Sequencing was per-
formed on all positive PCR products (Mayo Advanced Genomics Technol-
ogy Center) to confirm the identity of amplified genes.
To measure miR15a levels, a quantitative PCR approach using a LightCy-
cler (Roche) was employed. Expression of miR15a was assessed according 
to the TaqMan MicroRNA Assay protocol (Applied Biosystems). cDNA was 
synthesized from 2 μg of total RNA using miR15a-specific primers and the 
TaqMan MicroRNA Reverse Transcription Kit (both from Applied Biosys-
tems). PCR for miR15a was performed for 45 cycles at 95°C for 15 seconds, 
and annealing and extension steps were performed at 59°C. The data were 
analyzed using the comparative Ct method. Data are given as fold changes 
of average signals in normal and cystic cholangiocytes.
Immunofluorescence microscopy. NRCs and PCK-CCL were grown on 
cover slips, fixed with methanol (5 minutes at –20°C), and incubated 
overnight at 4°C with primary antibodies against acetylated tubulin 
(Sigma-Aldrich) at a dilution of 1:100 or Cdc25A (Santa Cruz Biotech-
nology Inc.) at a dilution of 1:100. Alexa Fluor 488 and Alexa Fluor 594 
(Invitrogen) were used as secondary antibodies (1:500 dilution), and 
nuclei were stained with DAPI.
Western and Northern blot analysis. Total protein was extracted with 
M-PER Mammalian Protein Extraction Reagent (Pierce; Thermo Scien-
tific), separated by sodium dodecyl sulfate/polyacrylamide electrophore-
sis, and transferred overnight to a nitrocellulose membrane; Cdc25A was 
detected using primary Cdc25A antibody (1:500 dilution; Santa Cruz Bio-
technology Inc.) and horseradish peroxidase–conjugated goat anti-mouse 
secondary antibody (1:1000 dilution; Sigma-Aldrich). β-actin served as a 
loading control. Protein bands were detected using an enhanced chemilu-
minescence detection system (Amersham; GE Healthcare).
For Northern blot, miRNAs were enriched from the total RNA (mirVana 
miRNA Isolation kit, Ambion; Applied Biosystems). miRNAs (1 μg) were 
separated on a 15% polyacrylamide gel and transferred to membrane. The 
probes for miRNAs and 5S RNA detections were synthesized using tem-
plates for miR15a (5′-TAGCAGCACATAATGGTTTGTGCCTGTCTC-3′, 
and 5S RNA (5′-GTTAGTACTTGGATGGGAGACCGCCCTGTCTC-3′). 
After incubation with 2.5 × 106 cpm per blot overnight at 42°C, membranes 
were washed and exposed to autoradiography films for 24–96 hours.
Flow cytometry. PCK-CCL transfected with miR15a was harvested, fixed 
with cold 70% EtOH, and suspended in propidium iodide (50 μg/ml); 
Figure 8
Effect of miR15a overexpression in cystic cholangiocytes on miR15a levels, cell proliferation, and cyst growth. (A) Quantitative PCR shows that 
in PCK-CCL stably transfected with the miR15a precursor (PCK-CCL–pSR-miR15a), levels of miR15a were increased compared with those in 
untransfected PCK-CCL or PCK-CCL transfected with EV (PCK-CCL–pSR-EV). (B) Cell proliferation was inhibited in PCK-CCL–pSR-miR15a 
compared with that in PCK-pSR-EV. Data are representative of 3 independent experiments. (C) Light microscopy analysis of PCK-CCL–pSR-EV 
and PCK-CCL–pSR-miR15a revealed the presence of cystic structures in 3D culture. Cysts formed by PCK-CCL–pSR-EV (top panels) continued 
to grow progressively over time while cystic structures formed by PCK-CCL–pSR-miR15a (bottom panels) did not expand. Scale bars: 250 μm. 
(D) Quantitative analysis of cystic areas demonstrates that rates of cyst growth in PCK-CCL–pSR-miR15a cultures (n = 13) were inhibited sig-
nificantly compared with those in PCK-CCL–pSR-EV cultures (n = 25). *P < 0.05.
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RNase A (0.1 mg/ml) was added. After incubation at 37°C for 30–45 
minutes, FACS analysis was performed at Mayo Advanced Genomics 
Technology Center.
Microarray analysis of endogenous miRNA expression. miRNA expression profil-
ing of NRCs and PCK-CCL was performed using GenoExplorer Microarray 
Biochip Platform (GenoSensor Corp.) that contains 254 miRNA sequences 
selected from the public database. 10 μg of total RNA was isolated from nor-
mal and cystic cholangiocytes and then labeled and hybridized to a commer-
cial microarray for analysis by the GenoSensor Corp. under optimized condi-
tions. The average of 3 mean fluorescence signal intensities for each precursor 
miRNA probe was normalized to that for tRNAmet. Precursor miRNAs detect-
ed at 2-fold greater than background were considered to be expressed. Data 
were analyzed with GenePix 5.0 software, provided by GenoSensor Corp.
Prediction of miRNA targets. Three well-known miRNA target prediction 
programs were used to search for miR15a targets: TargetScan 4.1 (http://
www.targetscan.org), miRBase Targets Version 5 (http://microrna.sanger.
ac.uk/targets/v5/), and PicTar (http://pictar.bio.nyu.edu). Through all of 
these programs, Cdc25A was identified as a predicted target of miR15a 
(conserved in human, mouse, and rat).
Genomic DNA PCR. 0.1 μg of genomic DNA was amplified using miR15a 
precursor–specific primers: sense (5′-AAGGCAAACCTGTTAAGTGTG-3′) 
and antisense (5′-GCACATCCAGTGATGGGTTT-3′). Each amplification 
reaction consisted of 35 cycles at 94°C for 1 minute, 55°C for 1 minute, 
and 72°C for 1 minute. PCR product was sequenced by Mayo Advanced 
Genomics Technology Center.
In situ hybridization. Liver tissue sections were deparaffinized, washed in 
PBS and deproteinated with proteinase K (10 μg/ml at 37°C). Sections 
were washed once in 0.2% glycine in PBS and twice in PBS, then fixed for 
10 minutes in 4% PFA. Prehybridization was performed in a humidified 
chamber (50% formamide, 5X SSC) using hybridization buffer (50% for-
Figure 9
Effect of miR15a suppression in normal cholangiocytes on miR15a levels, Cdc25A expression, cell proliferation, and cyst growth. (A) Repre-
sentative light (top panels) and fluorescent (bottom panels) images show that both scrambled miRNA and anti-miR15a were present in cultured 
cells in contrast with cholangiocytes treated with vehicle. Original magnification, ×20. (B) Quantitative PCR demonstrates that levels of miR15a 
in cholangiocytes treated with anti-miR15a (anti) were decreased compared with those in cholangiocytes treated with vehicle or scrambled 
miRNA. Data are representative of 3 independent experiments. (C) Representative Western blot and quantitative analysis based on densitometry 
measurements (D) of 5 independent experiments show that in anti-miR15a cholangiocytes, Cdc25A protein levels were increased by 38%. Thin 
white lines on the gel indicate that the lanes were run on the same gel but were noncontiguous. (E) Rates of cell proliferation were assessed in 
cholangiocytes treated with scrambled miRNA (n = 5) or anti-miR15a (n = 6) and expressed as a percentage of changes compared with rates of 
proliferation in nontreated cholangiocytes (considered to be equal to 100%). Cholangiocytes exposed to miR15a antisense display higher rates 
of proliferation than cholangiocytes exposed to scrambled miRNA. (F) Representative light microscopic images of cystic structures formed in 
3D culture by normal cholangiocytes and quantitative assessment of changes in cystic areas over time (G) reveal that in the presence of anti-
miR15a, cysts grow more rapidly compared with those in the presence of scrambled miRNA. Changes shown in G are in comparison with day 0. 
*P < 0.05. Scale bars: 250 μm.
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mamide, 5X SSC, 0.1% Tween, 9.2 mM citric acid for adjustment to pH 6, 
50 μg/ml heparin, and 500 μg/ml yeast RNA) for 2 hours. Slides were then 
hybridized overnight with 20 nM of FITC-labeled miR15a (CACAAAC-
CATTATGTGCTGCTA) or scrambled miRNA (TTCACAATGCGTTATC-
GGATGT; Exiqon) in a humidified chamber at 51°C. Liver sections were 
rinsed in 2X SSC, washed 3 times for 30 minutes in 50% formamide and 
2X SSC at hybridization temperature, and washed 5 times for 5 minutes 
in PBST at room temperature.
Establishment of transiently and stably transfected PCK-CCL. PCK-CCL 
(60%–70% confluent) was transfected using siPORT NeoFx Lipid-Based 
Reverse Transfection Reagent (AM-4511, Ambion; Applied Biosystems) 
or FuGENE Transfection Reagent (Roche), respectively. In brief, 5 μl of 
siPORT NeoFx was mixed with 100 μl of Opti-MEM (Invitrogen), incu-
bated for 10 minutes at room temperature, and then incubated for an 
additional 10 minutes with 20 nM (final dilution) of miR15a precursor 
oligonucleotides. PCK-CCL (2.5 × 105 cells) were suspended in this solu-
tion and plated. Western blot analysis for Cdc25A was performed 12 hours 
after transfection. PCK-CCL transiently transfected with FITC-labeled 
miR15a was used for confocal microscopy.
For FuGENE transfection, 3 μl of FuGENE Transfection Reagent (Roche) 
was added to 97 μl of Opti-MEM and incubated for 5 minutes at room 
temperature. 20 nM (final dilution) of miR15a precursor oligonucleotides 
were added to the FuGENE/Opti-MEM mixture, incubated for an addi-
tional 15 minutes, and applied to PCK-CCL (60%–70% confluent). Flow 
cytometry (FACS) analysis was performed 12 hours after transfection.
To establish a stably transfected PCK-CCL, a pSilencer vector (Ambion; 
Applied Biosystems) was constructed by inserting an 83-bp genomic sequence 
of miR15a precursor (PCK-CCL–pSR-miR15a). We used the following oligo-
nucleotides for the top strand and bottom strand, respectively: 5′-GATCC-
GCCCTTGGAGTAAAGTAGCAGCACATAATGGTTTGTGGA-TGTT-
GAAAAGGTGCAGGCCATACTGTGCTGCCAAAATACAAGGAGGAAA-3′ 
and 5′-AGCTTTTCCTCCTTGTATTTTGAGGCAGCACAGTATG-GCCTG-
CACCTTTTCAACATCCACAAACCATTAGTGCTGCTACTTTACTCCAA-
GGGCG-3′. The oligos were annealed and subsequently ligated with T4 DNA 
ligase into the pSilencer 4.1–CMV (Ambion; Applied Biosystems) expressing 
the puromycin cassette. PCK-CCL transfected with this plasmid construct 
and stably transfected cells were selected using puromycin (1 μg/ml).
Luciferase reporter constructs and luciferase assay. A 436-bp fragment of the 
3′-UTR region of rat Cdc25A mRNA that contains the miR15a target site 
was amplified by RT-PCR using specific primers sense 5′-TGAGTAC-
TAGTCCTTCCCTGTCAGGACTG-3′ and anti-sense 5′-CAGCTAAGCTT-
GCGCTGCCCACACTTAAC-3′ and cloned into pMIR-REPORT luciferase 
vector (Ambion; Applied Biosystems). The mutant Cdc25A mRNA 3′-UTR 
region (TGCTGCTG to TGCACCAG) was also constructed. PCK-CCL 
was transfected with each construct miR15a precursor oligonucleotide 
or scrambled miRNA, followed by assessment of luciferase activity at 
48 hours after transfection. Luciferase activity was normalized to TK Renil-
la construct as previously reported (40).
3D culture and cyst measurement. The cystic and normal cholangiocytes 
were grown in 3D culture as previously described (12). To study the effect 
of miR15a overexpression we used stable-transfected PCK-CCL. Develop-
ment of cystic structures was assessed by light microscopy at day 3 after 
seeding, and each cyst was followed up at days 6, 9, and 12. To study 
the effect of miR15a suppression on cyst growth, NRCs were seeded 
in 3D culture and treated with 50 nM of either anti-miR15a (Ambion; 
Applied Biosystems) or scrambled miRNA at days 0 and 2. Growth of 
cystic structures was assessed by light microscopy for 5 consecutive days. 
Using ImageJ software (http://rsbweb.nih.gov/ij/), we determined the 
cross-sectional area of normal and PCK cysts; data were expressed as a 
percentage of changes in cystic area compared with day 0 (i.e., day when 
cells were entered in 3D culture).
Statistics. All values were expressed as mean ± SEM. Statistical analysis was 
performed by 2-tailed Student’s t test, and results were considered statisti-
cally significant at P < 0.05.
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